The purpose of the study was to determine the role of transurethral resection of the prostate (TURP) to detect prostate cancer in patients with consistently negative transrectal ultrasound-guided biopsies of the prostate. We retrospectively identified and analysed the patients who also had at least two sets of transrectal ultrasound guided sextant prostate biopsies before their TURP during the period between 1998 and 2002. A total of 14 such patients were identified and the outcome of TURP was analysed. Three patients were found to have cancer in the resected specimen (3/14 ¼ 21%). All three cancers were significant (Gleason scores between 6 and 8) and required further treatment. In patients who have rising levels of prostate-specific antigen and who have had multiple negative peripheral zone biopsies, the presence of biologically important transition zone cancers needs to be considered. This can be detected by transurethral resection of the prostate that samples the transition zone of the prostate.
Introduction
The combination of digital rectal examination (DRE), prostate-specific antigen (PSA) and transrectal ultrasound (TRUS)-guided biopsy of the prostate is a widely accepted method for detecting prostate cancer. Although PSA is regarded as the best marker at present for early detection of prostate cancer, 1 in practice, only 21% of men with a PSA between 4 and 10 ng/ml and normal DRE have prostate cancer 2 and as a result the majority of men in this group undergo prostate biopsy unnecessarily. Derivatives of PSA-like free PSA, complex PSA, PSA density, etc are the focus of much ongoing research in an attempt to improve the specificity of PSA as a tumour marker. In addition, the role of routine TRUSguided sextant biopsy of the prostate has been called into question, prompting many clinicians to modify and extend their biopsy regimen in an attempt to improve diagnostic yield. Despite the development of extended core biopsies and laterally placed peripheral zone biopsies, prostate cancers can still be missed.
In patients who have rising levels of PSA the decision to proceed to repeat prostate biopsies can be difficult both for the clinician and the patient. Repeat TRUS biopsies have a cancer detection rate of 10% 3 and subsequent detection rates are only 5% for the third biopsy and 4% for the fourth biopsy 4 in patients with PSA between 4 and 10 ng/ml (normal value is between 0 and 4 ng/ml). If patients with PSA greater than 10 ng/ml are also considered, the rate of cancer detection is higher. In a study conducted in our institution, out of 48 patients who underwent repeat sextant TRUS biopsies, 22% had cancer on second biopsy and 8.3% had cancer detected in their third and subsequent biopsies and the mean PSA levels in this study was 16.9 ng/ml. 5 Morbidity also increases after the third set of biopsies. 4 The question is what is the optimal management of patients who have rising levels of PSA despite multiple previous biopsies being negative? The known multifocal nature of prostate cancer coupled with the relatively small volume of tissue sampled with systematic prostate biopsies raises the possibility that significant cancer may exist within the gland despite negative biopsy result.
Many studies have addressed the question of why cancers are missed on TRUS biopsies. One of the factors is location of cancers in the transition zone (TZ) which constitute about 24% of all prostate cancers. 6 Hence, some studies have advocated the addition of TZ biopsies to conventional systematic sextant biopsies of the prostate but this is still controversial. This is discussed elsewhere in the paper. The other method to sample the transition zone is by transurethral resection of prostate (TURP) and very few studies have addressed this issue. TURP samples a large volume of TZ which may allow detection of cancers not identified by conventional prostate biopsy techniques.
We retrospectively analysed all the patients who had TURP after two or more negative TRUS biopsies to determine the role of transurethral resection of the TZ by TURP in detecting prostate cancers which are not detected by routine systematic sextant peripheral zone biopsies and to analyse the nature of cancers detected by this method.
Materials and methods
In all, 719 patients underwent TURP in our institution during the period between 1998 and 2002. We gathered data on all patients among this group who also had at least two sets of TRUS-guided transrectal prostate biopsies. A total of 14 such patients were identified. The indications for biopsy in these patients were an elevated PSA of greater than 4 ng/ml or when malignancy was suspected on DRE. Patients who had lower urinary tract symptoms (LUTS) were commenced on alpha blockers as indicated. None of these 14 patients were started on 5 alpha-reductase inhibitors as it is known to reduce the PSA levels to lower values.
TRUS-guided biopsies were performed with a BK Med Falcon 2101 ultrasound scanner (Sandotoften 9, DK 2829, Gentofte) using a 7.5 MHz bipolar transrectal probe and 18-gauge needle on a spring-loaded gun (CR Bard, Covington, GA, USA). PSA assay was carried out using DPC Immulite 2000 chemiluminescence assay. Prostate volume was measured using the formula height Â weight Â length Â 0.523. The number of cores taken during the biopsy was determined by the prostate size and the visualisation of any hypoechoeic lesions in the prostate and standard sextant biopsy technique was used. However, on the subsequent biopsies, these 14 patients had atleast one extended core biopsy varying from 8 to 12 cores. However, even though the 10 core biopsy protocol is now the standard technique in our institution, this was not our policy during the period of the study. PSA density was calculated by dividing serum PSA by total prostate volume.
Patients whose initial sets of biopsies were negative for malignancy were reviewed, counselled regarding prostate cancer risk and continued under observation. They underwent repeated PSA examinations and biopsies were repeated if the PSA continued to rise. The decision to subject the patient to further biopsy was dependent on the clinician's assessment of prostate cancer risk in that particular patient.
All the patients who had at least two negative biopsies were offered TURP to sample the transition zone for diagnosing TZ cancers. Four out of these 14 patients had lower urinary tract symptoms or developed these symptoms during the follow-up period. Their symptoms were controlled medically with alpha blockers during the period they were awaiting TRUS biopsies or were under follow-up. Two patients presented in retention during the period (cases 6 and 11). The rest of the eight patients were offered TURP as a diagnostic procedure to sample the TZ. It was decided to offer TURP to these patients as they form a particularly difficult subset of patients in whom the PSA keeps rising despite previous negative prostate biopsies and thus have a considerable risk of prostate cancer. As discussed later in the paper there is a considerable chance that they might harbour TZ cancers that are difficult to diagnose otherwise. It was particularly important to detect cancer in these patients as they were young in whom early detection of cancer can achieve cure. Although the patients had TURP for various indications, the factor common to all of these patients is raising levels of PSA despite multiple negative peripheral zone biopsies. Patients were counselled regarding the reason behind suggesting TURP and the morbidity and mortality of the procedure and informed consent was obtained. These patients were also offered further TRUS biopsies as an alternative, but they readily accepted TURP as an option.
TURP was performed to the surgical capsule to maximise the yield of a positive diagnosis of cancer. All the cases were discussed with the pathologist and all of the prostate chips from TURP were processed and examined. The cancers found were graded according to the Gleason system. Volume of cancer was calculated as the number of chips positive for prostate cancer divided by total number of chips resected.
Results
Of the 14 patients in the study group, 11 patients were primarily referred for raised PSA and three patients primarily for LUTS who were found to have raised PSA or suspicious DRE findings in the urology clinic. The age of these patients varied from 54 to 83 years (median of 62.5). Overall, 10 patients had two sets of TRUS biopsies, three patients had three sets of biopsies and one patient four sets of TRUS biopsies. Initial PSA values varied from 4.2 to 26.8 ng/ml. The clinico-pathological variables of these two groups of patients are summarised in Tables 1  and 2 . Cancer-related variables between patients detected to have cancers on TURP and those whose TURP specimens were benign are given in Table 3 .
Three patients were noted to have cancer in the resected specimen (3/14 ¼ 21%). All three cancers were significant and required further treatment. Clinically insignificant cancers have been defined as small volume tumour (0.5 cm 3 or less) without a Gleason 4 or 5 component. 7 The Gleason score of the cancers were between 6 and 8. We describe these cancers in detail.
(1) Case number 12 had three sets of prostate biopsies. PSA before third set of TRUS biopsy was 31.0 ng/ml and before TURP was 33.3 ng/ml. TURP revealed carcinoma of the prostate of Gleason score 8 with cancer in 3/200 chips resected (cancer volume of 1.5%). Due to high TURP after multiple negative transrectal prostate biopsies S Radhakrishnan et al grade of the cancer, the patient was treated with a LHRH analogue.
(2) Case number 13 had four sets of prostate biopsies. PSA before the fourth set of prostate biopsy was 32.1 ng/ml and before TURP was 44.5 ng/ml. TURP revealed carcinoma of the prostate of Gleason score 7 with cancer in 17/70 chips (cancer volume of 24%). Staging MRI had shown that the cancer was confined to the prostate gland and this patient was treated with radical radiotherapy. He died of a bleeding duodenal ulcer 27 months later.
(3) Case number 14 had two negative sets of TRUS biopsies and TURP revealed carcinoma of the prostate of Gleason score 6 with cancer in 2/60 chips (cancer volume of 3.3%). The PSA before the 2nd TRUS biopsy and before TURP was 5.6 ng/ml. This patient underwent radical conformational radiotherapy as a previous severe crush injury to the pelvis had caused severe deformity to the pelvic outlet.
During the follow-up of patients in whom TURP were negative for malignancy, PSA of seven patients had fallen to normal values after TURP and hence were discharged from follow-up. One patient has required repeat extended core biopsy after TURP (case no. 10). It has shown Gleason 3 þ 4 ¼ 7 carcinoma in one core out of 16 cores occupying 20% of area submitted. The PSA of the other three patients remained stable during the followup period of between 12 and 24 months.
Discussion
The management of patients who have persistently raised PSA despite previous negative TRUS-guided prostate biopsies is a common problem encountered by the urologist. McNeal et al 6 reported that the distribution of prostate cancers was 68% in the peripheral, 8% in the central and 24% in the TZs. In men with previous negative prostate biopsies and persistently elevated serum PSA, the role of undetected TZ cancer must be considered. Detection of TZ cancers remains important since it has been reported that some TZ cancers are clinically or pathologically significant. 7, 8 Digital rectal examination is a particularly poor detector of TZ cancer, because the anterior location of the TZ and intervening peripheral zone results in TZ tumuors being perceived as generalised enlargement and mistaken for the more common BPH. 9 Imaging studies like TRUS or MRI have not proved reliable in the identification of TZ cancers. 10, 11 Prostate cancers are often multifocal and the volume of prostate sampled by standard sextant technique is relatively small. More recent development of extended core biopsy protocols focus on lateral placement of TRUS-guided biopsies in the peripheral zone. 12 However, despite this modification in biopsy protocols, we may miss cancer. TZ biopsy may help to detect TZ cancers. However, its efficacy is still controversial and TURP after multiple negative transrectal prostate biopsies S Radhakrishnan et al this is discussed elsewhere in the paper. An alternative to transrectal TZ biopsy is TURP. An argument in favour of TURP is that it generally samples tissue from TZ of the prostate 13 and also provides a large volume of TZ tissue and hence may detect cancers which were not detected by conventional biopsy techniques. Very few studies have addressed this issue. Our study has indicated that we can detect cancer of the TZ in 21% of patients after previous negative peripheral zone biopsies. Furthermore, the cancers detected were clinically significant which has major implications as these patients were relatively young.
Ornstein et al 14 reviewed patients who had symptomatic BPH with associated elevated serum PSA and/or suspicious DRE and had at least one set of benign systematic prostate biopsies. Cancer was detected in the TURP specimens in 16.1% (9/56) patients and 89% of these were of clinical stage T1b or higher. Kitamura et al 15 examined the role of TURP in detecting cancers undiagnosed with single systematic sextant and TZ biopsies and reported a cancer detection rate of 28% but concluded that the cancers detected were clinically insignificant as all patients had Gleason sum scores between 2 and 5. In this study, Kitamura used transperineal TZ biopsy in addition to systematic sextant biopsy and looked into cancer detection rate after TURP after single biopsy. The patients in his study were also offered TURP for accepted indications. Routine transperineal TZ biopsy was not the routine practice in our institution and the TURP was only offered in a difficult subset of patients whose PSA was rising despite two negative biopsies. In our study, eight out of 14 patients were offered TURP as a diagnostic procedure. A more recent retrospective review by Zigeuner et al 16 has shown a cancer detection rate by TURP in patients with two or more biopsies to be 7.6% (10 out of 28 patients), but this paper did not comment on the significance of cancer detected on TURP.
In advocating a policy of transurethral resection of the prostate for routine clinical use, we need to address a number of issues. These include the role of transrectal TZ biopsy in detecting TZ cancers, the nature of cancer detected on third and subsequent TRUS biopsies, the associated morbidity and whether cancers detected by TURP are clinically significant.
Lui et al 17 examined the indications for TZ biopsy in men with suspected prostate cancer with elevated PSA and normal DRE and found that 33.3% of patients had cancer confined exclusively to the TZ. Reissigl et al 7 reported that in sextant combined with TZ biopsies, 8.2% of patients who presented with serum PSA elevation and normal DRE had cancers that originated in the TZ alone. They concluded that TZ biopsy should be added to the routine sextant biopsy, since a significant number of locally invasive cancers were found in the TZ. However, other studies have reported markedly lower cancer detection rates. 18, 19 It is possible that the incidence of positive TZ biopsies in screen-detected (asymptomatic) patients is lower than in patients presenting with lower urinary tract symptoms in conjunction with a raised PSA which may be responsible for the markedly varied results among the above studies. From our experience, such patients are more commonly seen in the UK and more than 10% of such individuals will have isolated TZ tumours. 20 Overall, however, the low diagnostic yield of systematic TZ biopsy strongly argues against their routine clinical use for early detection of cancer.
The European prostate cancer detection study 3 has conclusively established that the cancers detected at third and subsequent biopsy are of low volume, stage and Gleason score and the complication rates for third and fourth biopsy are slightly higher than first and second biopsy. It was concluded that biopsies 3 and 4 should only be performed in selected patients with a high suspicion of cancer and/or poor prognostic factors on biopsy 1 or 2. This recommendation was for patients with PSA between 4 and 10 ng/ml. However it can be argued that if cancer is not detected on the second set of TRUS biopsies, there may be a role for sampling the TZ, which is best performed by TURP.
While the biological significance of TZ cancers has been debated, Stamey et al 8 clearly demonstrated that a large proportion of such cancers are clinically significant. In their series of radical prostatectomy 48% of cancers originating from the TZ were larger than 7 cm 3 and 23% had more than 20% or more Gleason grade 4 or greater. Also, it has been shown that TZ cancers are frequently associated with a separate larger and higher grade peripheral zone cancer in radical prostatectomy specimens. 21 Several studies have shown that prostate cancers found on TURP progress and may negatively impact survival if left untreated. Epstein et al 22 reported with a follow-up for 8 y, that 14 % patients with untreated clinical stage A2 prostate cancer, detected on TURP had progression to metastatic disease and 12% died as a direct result of advanced prostatic cancer. This demonstrates the potential aggressive behaviour of transurethral resection detected clinical stage T1 tumours and underline the importance of diagnosing these TZ cancers.
All the previous studies have examined the role of TURP and cancer detected after one or more sets of sextant biopsies combined with TZ biopsy. However, the present series shows a particularly difficult subset of patients who have rising levels of PSA and in whom second or subsequent peripheral zone biopsies fail to provide a definitive diagnosis and in whom further biopsies may increase morbidity .We were able to detect cancers in 21% of such patients by TURP and all the cancers detected in our series were significant. Although our study is limited by the fact that the power of the study is too small to draw any firmer conclusions, this does throw some light on the potential usefulness of TURP in such a difficult situation in this particularly difficult subset of patients. TURP has a known mortality rate of 0.2%, an inpatient complication rate of 10% and a 35% complication rate after discharge from hospital. 23 These factors need to be considered when counselling the patient. The series of patients described in this study is very infrequent in clinical practice but presents a very difficult subset of patients with diagnostic dilemma and hence we recommend that they should undergo TURP to make sure we do not miss TZ cancers accepting the morbidity of the procedure.
There have been few studies looking into the role of transurethral sampling of the TZ using four quadrant sampling of prostatic fossa. 24, 25 However these studies concluded that the diagnostic yield was low and misses cancers that were diagnosed by a TURP to the surgical TURP after multiple negative transrectal prostate biopsies S Radhakrishnan et al capsule and hence it was not recommended for routine use. The amount of tissue yield is low in transurethral sampling and hence a proper TURP to the surgical capsule should be carried out.
Conclusions
In patients who have raised PSA and who have had multiple negative peripheral zone biopsies, the presence of biologically important TZ cancers needs to be considered. This can be detected by TURP biopsies of the TZ. Although our study is limited by the small number of patients, this study has indicated that TURP may be useful in such a clinical scenario.
